Nanomedical Diagnostics Announces Partnership with Rogue Valley Microdevices, Delivering World’s First Successful High-Volume Manufacturing for Graphene Biosensors

Share Article

AGILE R100, a kinetic binding platform created by the cost-effective, high-throughput fabrication process, gives pharmaceutical companies access to a novel label-free biophysical characterization tool for the first time.

AGILE R100 Label-Free Graphene Biosensor

The AGILE R100 Label-Free Graphene Biosensor

The ability to manufacture graphene biosensors at scale will enable us to create significant cost reductions for many life science and healthcare applications, as well as introduce game-changing capabilities that have never been seen before.

Biotech company Nanomedical Diagnostics teams with full-service MEMS foundry Rogue Valley Microdevices to deliver the only mass-produced graphene biosensor available, AGILE R100. Previously, the benefits of graphene biosensor technology were restricted to specialized, well-funded university labs building one-off platforms. The new partnership between Nanomedical Diagnostics and Rogue Valley Microdevices has opened the novel sensing technique to any pharmaceutical company seeking to characterize biomolecules quickly and easily, transforming the field of drug discovery.

Graphene has been touted as the world’s most versatile material capable of revolutionizing biomedical applications due to its excellent electrical conductivity, high surface area, and unique biocompatibility. Studies on the detection of biomolecules using lab-produced graphene-based biosensors have shown the sensors to exhibit high sensitivities, wide linear detection ranges, and low detection limits. Numerous efforts have been made by companies to commercialize graphene biosensors at scale, but the process was hampered due to the difficulty of integrating delicate graphene material into standard high-volume production processes.

Nanomedical Diagnostics together with Rogue Valley Microdevices has solved the riddle, overcoming substantial manufacturing hurdles to bring the label-free kinetic binding assay AGILE R100 to market. AGILE R100 is designed to provide biophysical data to pharmaceutical and biotherapeutics companies seeking more informed decisions earlier in the drug discovery process. However, with the most difficult piece of the puzzle – cost-effective large-scale manufacturing – solved, the company plans a significant impact on the healthcare industry with innovative new products that enable cutting-edge life science research, drug discovery applications, and diagnostic and health monitoring platforms.

“Rogue Valley Microdevices has been a true partner in developing a viable large-scale fabrication process for our AGILE biosensor chips,” says Nanomedical Diagnostics founder and CEO, Ross Bundy. “Their world-class process engineers enabled AGILE R100 to be manufactured with high reproducibility, quality, and throughput, which provides better data and lower costs for our customers. In the long run, the ability to manufacture graphene biosensors at scale will enable us to create significant cost reductions for many life science and healthcare applications, as well as introduce game-changing capabilities that have never been seen before.”

“When Nanomedical Diagnostics approached us with the AGILE R100 design, we recognized the opportunity to get in on the ground floor of a revolution,” says Jessica Gomez, founder and CEO of Rogue Valley Microdevices. “We have codeveloped the only graphene biosensor fabrication process in existence and are now the pre-eminent experts in that field.”

Nanomedical Diagnostics will be at the 2017 American Chemistry Society National Meeting in San Francisco to present AGILE R100 and the unique graphene biosensor technology behind the platform. Visit booth 1434 from April 2 through 4 to learn more.

About Nanomedical Diagnostics

Nanomedical Diagnostics (“Nanomed”) is a biotech company based in San Diego, CA. Nanomed has developed a breakthrough electronic assay based on Field Effect Biosensing (FEB) technology that provides real-time, label-free kinetic binding and affinity data. Biosensors at the heart of the assay leverage the highly sensitive nanomaterial graphene to unite biology with electronics, delivering the unique ability to sense molecules >1 Da in complex media such as DMSO, and use unprecedentedly small amounts of sample.

About Rogue Valley Microdevices

Rogue Valley Microdevices is a full-service precision MEMS foundry that combines state-of-the-art process modules with the engineering expertise to go seamlessly from custom design to manufacturing. Specializing in MEMS and biomedical device manufacturing, Rogue Valley Microdevices offers a flexible equipment set and smaller batch sizes, playing a critical role in the commercial MEMS manufacturing ecosystem.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Angela Shue
Visit website